Medtronic PLC (MDT) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.

Total Cash From Operating Activities Chart for Medtronic PLC

Medtronic PLC (MDT) operating cash flow for FY2026 was USD 7.3B, a 4.1% change from FY2025. Medtronic PLC's operating cash flow grew from USD 106.8M in 1990 to USD 7.3B in 2026 (6763.3% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of 3.3%, 10-year CAGR of 3.5%, 20-year CAGR of 6.2%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$117.99B
Implied Share Price
$92.18
Enterprise Value
$136.55B
Revenue (TTM)
$36.36B
EBITDA
$10.10B
Profit Margin
13.20%
Trailing P/E
24.71
Forward P/E
15.43
Price/Book (MRQ)
2.38
Price/Sales (TTM)
3.24
EV/EBITDA
13.92
EV/Revenue
3.76
Dividend Yield
0.00%
Book Value
$38.64
Free Cash Flow (FY2026)
$5.43B
Free Cash Flow Yield
4.60%

Snapshot as of 3rd September 2026 — not point-in-time controlled, may lag the live market by a few days.